Review Article
The Diagnostic Power of Circulating miR-1246 in Screening Cancer: An Updated Meta-analysis
Table 2
Subgroup meta-analyses for sensitivity, specificity, and DOR.
| Variable | Number of study | Number of case | Sensitivity | Specificity | DOR | Estimates, % (95% CI) | , % | | | Estimates, % (95% CI) | , % | | | Estimates, % (95% CI) | , % | | |
| Cancer type | | | | | | 0.106 | | | | <0.001 | | | | <0.001 | BC | 7 | 3321 | 91.8 (83.9-95.9) | 70.6 | 0.001 | | 90.4 (84.9-94.0) | 73.5 | <0.001 | | 98.5 (72.2-134.2) | 29.4 | 0.194 | | CRC | 4 | 483 | 89.5 (55.2-98.3) | 86.3 | <0.001 | | 87.1 (67.4-95.7) | 73.3 | 0.011 | | 47.6 (5.6-401.3) | 87.1 | <0.001 | | ESCC | 3 | 620 | 78.3 (70.2-84.6) | 67.1 | 0.016 | | 68.0 (61.6-73.9) | 0.0 | 0.776 | | 8.0 (5.4-11.8) | 0.0 | 0.588 | | HCC | 4 | 328 | 77.1 (65.5-85.6) | 67.4 | 0.027 | | 87.5 (78.1-93.3) | 0.0 | 0.751 | | 18.6 (9.7-35.5) | 29.7 | 0.234 | | PC | 3 | 301 | 84.7 (78.6-89.3) | 61.9 | 0.072 | | 68.0 (59.3-75.6) | 0.2 | 0.367 | | 12.3 (5.6-26.9) | 30.2 | 0.239 | | Others† | 8 | 861 | 80.3 (72.6-86.3) | 74.0 | <0.001 | | 89.5 (77.9-95.3) | 46.4 | 0.061 | | 27.5 (10.3-73.5) | 75.9 | <0.001 | | Control type | | | | | | 0.292 | | | | <0.001 | | | | 0.068 | HC | 26 | 5552 | 84.8 (79.7-88.8) | 82.9 | <0.001 | | 86.5 (81.6-90.3) | 82.9 | <0.001 | | 31.5 (19.1-52.1) | 87.2 | <0.001 | | Benign | 3 | 362 | 77.8 (61.5-88.5) | 83.4 | 0.002 | | 68.2 (60.9-74.6) | 50.8 | 0.131 | | 8.6 (2.3-31.7) | 77.8 | 0.011 | | Sample type | | | | | | 0.479 | | | | 0.049 | | | | 0.008 | Plasma | 9 | 544 | 89.1 (77.9-94.9) | 64.4 | 0.004 | | 92.0 (85.8-95.7) | 0.0 | 0.716 | | 85.8 (30.1-244.0) | 50.5 | 0.040 | | Serum | 19 | 5101 | 82.5 (76.4-87.3) | 87.4 | <0.001 | | 82.7 (77.1-87.1) | 88.4 | <0.001 | | 21.3 (12.2-37.3) | 91.8 | <0.001 | | Others | 2 | 269 | 85.2 (78.2-90.3) | 56.0 | 0.103 | | 76.8 (43.0-93.6) | 0.0 | 0.917 | | 12.5 (6.7-23.5) | 0.0 | 0.520 | | Sample size | | | | | | 0.613 | | | | 0.004 | | | | 0.048 | ≥100 | 14 | 1039 | 85.7 (77.0-91.5) | 65.3 | <0.001 | | 79.3 (73.0-84.5) | 91.9 | <0.001 | | 18.8 (10.2-34.5) | 93.6 | <0.001 | | <100 | 15 | 4875 | 83.3 (77.4-87.9) | 88.4 | <0.001 | | 91.9 (85.5-89.2) | 23.3 | 0.185 | | 50.3 (23.4-108.2) | 59.2 | 0.001 | | Technique | | | | | | 0.009 | | | | <0.001 | | | | <0.001 | RT-qPCR | 23 | 2995 | 81.7 (76.3-86.2) | 79.2 | <0.001 | | 82.5 (77.1-86.9) | 53.0 | <0.001 | | 19.7 (12.4-31.3) | 75.9 | <0.001 | | Others | 6 | 2919 | 92.6 (86.1-96.2) | 16.2 | 0.310 | | 93.4 (92.0-94.5) | 0.0 | 0.598 | | 109.5 (83.9-142.9) | 4.3 | 0.389 | | Data extraction | | | | | | <0.001 | | | | 0.016 | | | | 0.675 | Direct | 21 | 5420 | 86.9 (82.2-90.5) | 82.1 | <0.001 | | 82.2 (76.7-86.6) | 87.9 | <0.001 | | 28.6 (16.1-50.8) | 90.8 | <0.001 | | Indirect | 8 | 494 | 71.2 (61.4-79.4) | 55.7 | 0.027 | | 92.6 (85.7-96.3) | 0.0 | 0.642 | | 23.1 (10.2-52.3) | 37.6 | 0.129 | |
|
|
BC: breast cancer; CRC: colorectal cancer; DOR: diagnostic odds ratio; ESCC: esophageal squamous cell carcinoma; HC: healthy control; HCC: hepatocellular carcinoma; PC: pancreatic cancer; PCa: prostate cancer; RT-qPCR: reverse transcriptase quantitative polymerase chain reaction; 95% CI: 95% confidence interval. Significance for heterogeneity; significance between subgroups; †including gallbladder cancer ( ), gastric cancer ( ), melanoma ( ), multiple myeloma ( ), non-small-cell lung cancer ( ), ovarian cancer ( ), prostate cancer ( ), and pancreatobiliary tract cancer ( ). |